[1]BRAY F，FERLAY J，SOERJOMATARAM I，et al.Global cancer statistics 2018：Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
[2]ZHANG C，ZHANG C，WANG Q，et al.Differences in stage of cancer at diagnosis，treatment，and survival by race and ethnicity among leading cancer types［J］.JAMA Netw Open，2020，3(4)：e202950.
[3]KHELWATTY SA，ESSAPEN S，SEDDON AM，et al.Prognostic significance and targeting of HER family in colorectal cancer［J］.Front Biosci(Landmark Ed)，2013，18：394-421.
[4]SONG Y，WANG L，RAN W，et al.Effect of tumor location on clinicopathological and molecular markers in colorectal cancer in eastern China patients：An analysis of 2 356 cases［J］.Front Genet，2020，11：96.
[5]OGAWA K，SAEKI N，IGURA Y，et al.Complementary expression and repulsive signaling suggest that EphB2 and Ephrin-B1 are possibly involved in epithelial boundary formation at the squamocolumnar junction in the rodent stomach［J］.Histochem Cell Biol，2013，140：659-675.
[6]OGAWA K，TAKEMOTO N，ISHII M，et al.Complementary expression and repulsive signaling suggest that EphB receptors and Ephrin-B ligands control cell positioning in the gastric epithelium［J］.Histochem Cell Biol，2011，136：617-636.
[7]DAVALOS V，DOPESO H，VELHO S，et al.High EphB2 mutation rate in gastric but not endometrial tumors with microsatellite instability［J］.Oncogene，2007，26：308-311.
[8]MIYAZAKI K，INOKUCHI M，TAKAGI Y，et al.EphA4 is a prognostic factor in gastric cancer［J］.BMC Clin Pathol，2013，13：19.
[9]NAKAMURA R，KATAOKA H，SATO N，et al.EphA2/EFNA1 expression in human gastric cancer［J］.Cancer Sci，2005，96：42-47.
[10]王永占，高青.EphB2在结肠癌组织中的表达及其与血管生成的关系［J］.癌变?畸变?突变，2008，20(04)：308-311.
WANG YZ，GAO Q.Expression of EphB2 in color carcinoma and its relationship with angiogenesis［J］.Carcinogenesis，Teratogenesis and Mutagenesis，2008，20(04)：308-311.
[11]MALDONADO V，MELENDEZ-ZAJGLA J.Role of Bcl-3 in solid tumors［J］.Mol Cancer，2011，10：152.
[12]PUVVADA SD，FUNKHOUSER WK，GREENE K，et al.NF-κB and Bcl-3 activation are prognostic in metastatic colorectal cancer［J］.Oncology，2010，78(3/4)：181-188.
[13]BROWN JC，ZHANG S，OU FS，et al.Diabetes and clinical outcome in patients with metastatic colorectal cancer：Calgb 80405(Alliance)［J］.JNCI Cancer Spectr，2019，4(1)：pkz078.
[14]URBAN BC，COLLARD TJ，EAGLE CJ，et al.BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling［J］.Gut，2016，65(7)：1151-1164.
[15]THAMKACHY R，KUMAR R，RAJASEKHARAN KN，et al.ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models：Efficiency of DAT1 in Ras-Raf mutated cells［J］.Mol Cancer，2016，8（15）：22.